Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer Patients

NCT05230888 | Withdrawn

• 1 other identifier: V1.1 10.09.2021
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer is responsible for one of the highest incidences of cancer-related mortality globally, and non-small cell lung cancer (NSCLC) accounts for the biggest subtype of lung cancer. In recent years, the use of immunotherapy has revolutionised the management of NSCLC, with better response rates and survival outcomes reported in the literature, compared to traditional cytotoxic chemotherapy. Despite this, doubts remain regarding the true efficacy of immunotherapy in patients \> 75 years old, given that this age subgroup is mis-represented in prospective phase III trials, in terms of numbers and baseline functional status, compared to real-world experience. Furthermore, the use of immune checkpoint inhibitors (ICIs) is associated with a spectrum of immune-related adverse events (irAEs), affecting a range of organ systems. Once again, there are doubts about the safety of the use of these agents in patients \> 75 years old, and whether baseline performance status and comorbidities are good predictors of efficacy and safety outcomes in this elderly patient subgroup. Comprehensive Geriatric Assessment (CGA) and the vulnerable elders survey (VES-13) are assessment tools that provide a good indication of functional status in elderly patients, in a similar capacity to performance status and comorbidities. This study therefore aims to prospectively examine patients \> 70 years old with a diagnosis of NSCLC, commencing immunotherapy. It will assess CGA and VES-13 scores at baseline, and correlate this with certain outcomes such as the incidence of severe adverse effects from immunotherapy at 3 and 6 months, any admissions to hospital arising from immunotherapy toxicities (and the subsequent length of inpatient stay), and mortality within 30 days. In doing so, it will help to determine if CGA and VES-13 scores can be used as a reliable indication of possible future efficacy and toxicity outcomes in this elderly patient subgroup.

Conditions

Lung Cancer; Non-small Cell Lung Cancer

Outcome Measures

Primary Outcomes (6)

• Incidence of irAEs at 3 months.

  At 3 months after entering the study.

• Nature of irAEs at 3 months.

  At 3 months after entering the study.

• Grading of irAEs at 3 months.

  At 3 months after entering the study.

• Incidence of irAEs at 6 months.

  At 6 months after entering the study.

• Nature of irAEs at 6 months.

  At 6 months after entering the study.

• Grading of irAEs at 6 months.

  At 6 months after entering the study.

Secondary Outcomes (4)

• Incidence of re-admission into hospital at 3 months.

  At 3 months after entering the study.

• Incidence of re-admission into hospital at 6 months.

  At 6 months after entering the study.

• Duration of inpatient stay (conditional on re-admission into hospital).

  Up to 12 months after entering the study.

• Death within 30 days (if applicable).

  Within 30 days of entering the study.

Study Arms (1)

Cohort

The effect of immunotherapy treatment will be assessed using the comprehensive geriatric assessment (CGA) and vulnerable elders survey (VES-13) in 100 non-small cell lung cancer patients, aged ≥70 years old, receiving immune checkpoint inhibitor (ICI) treatment.

Other: Questionnaires about symptoms

Interventions

Questionnaires about symptoms OTHER

The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).

Cohort

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

NSCLC patients ≥70 years old receiving ICI treatment at the Queen's Centre for Oncology and Haematology, Hull.

You may qualify if:

• Patients ≥70 years old with advanced NSCLC due to start first or second line ICI therapy.
• Patients able to give informed consent.

You may not qualify if:

• Patients already on treatment with ICIs.
• Patients with CNS or leptomeningeal spread / disease progression.
• ECOG performance status III/IV.
• Patients with severe autoimmune diseases.
• Patients who are recruited and then stop treatment after receiving ≤3 cycles of ICI therapy, secondary to disease progression.

Sponsors & Collaborators

• University of Hull: lead
• Hull University Teaching Hospitals NHS Trust: collaborator

Study Sites (1)

Castle Hill Hospital

Cottingham, Hull, HU16 5JQ, United Kingdom

Location

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2022
• First Posted: February 9, 2022
• Study Start: February 9, 2022
• Primary Completion: November 1, 2022
• Study Completion: November 1, 2022
• Last Updated: September 1, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)